---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-21-000025"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T10:12:23.241830+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Maravai Q3 revenue up 133% to $204.8M; raises 2021 guidance, provides 2022 outlook

## Summary
- Q3 revenue $204.8M (+133% YoY); net income $132.8M (+240%); Adj EBITDA $156.0M.
- Nucleic Acid Production revenue $182.9M (+170% YoY) on demand for CleanCap mRNA vaccine components.
- 2021 guidance raised: revenue $770-780M, Adj EBITDA $570-575M, Adj diluted EPS $1.48-$1.52.
- Initial 2022 revenue guidance $840-880M, representing ~11-14% growth at midpoint after adjusting for divestiture.
- Completed sale of Protein Detection business; published inaugural ESG report.

## SEC filing metadata
- accession: 0001823239-21-000025
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323921000025/0001823239-21-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323921000025/mrvi-20211110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-21-000025
- JSON: https://secwatch.observer/filing/0001823239-21-000025.json
- Plain text: https://secwatch.observer/filing/0001823239-21-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.